Post merger Astex ends SuperGen epigenetic deal with GSK
This article was originally published in Scrip
Executive Summary
A collaboration between SuperGen and GlaxoSmithKline (GSK) to discover cancer therapeutics is being terminated with assets generated under the deal being transferred to GSK. This follows the recent merger of SuperGen and Astex Therapeutics.